2023-509460-19-00招募中2 期
A phase 1b-2 study of mitomycin-C / capecitabine chemoradiotherapy combined with ipilumimab and nivolumab or nivolumab monotherapy as bladder sparing curative treatment for muscle invasive bladder cancer: the CRIMI study
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- In the phase Ib study: toxicity scored with CTCAE v 4.03; incidence of dose limiting toxicity (DLT) during the first 6 weeks after start of the combination
研究概览
简要总结
*to assess toxicity *to assess the feasibility and safety of the addition of nivolumab and/or ipilimumab to MMC/capecitabine chemoradiation of the bladder. *to assess the feasibility , the disease free survival (DFS) and disease free survival rate (DFS-rate) of the addition of nivolumab and/or ipilimumab to MMC/capecitabine chemoradiation of the bladder
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Be willing and able to provide written informed consent for the trial.
- •Demonstrate adequate organ function as defined below. All screening labs should be performed within 28 days of registering the patient on the trial. Screening laboratory values must meet the following criteria: - WBCs ≥ 2000/μL - Neutrophils ≥ 1500/μL - Platelets ≥ 100 x 10³/μL - Hemoglobin ≥ 5.5 mmol/l - creatinine clearance (CrCl) ≥ 40 mL/minute (using Cockcroft/Gault formula or better) - AST ≤ 3 x ULN vii) ALT ≤ 3 x ULN - Total Bilirubin ≤ 1.5 x ULN (except for subjects with Gilbert Syndrome a total bilirubin ≤ 50 umol/L) - Albumin ≥ 30 mg/L - Lipase ≤ 1.5 ULN. Subjects with Lipase ≥ 1.5 ULN may enroll if there are neither clinical nor radiographic signs of a pancreatitis. - Amylase ≤ 1.5 ULN. Subjects with Amylase > 1.5 ULN may enroll if there are neither clinical nor radiographic signs of a pancreatitis.
- •Female participants of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to registering the patient. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •Female participants of childbearing potential should be willing to one highly effective method of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 5 month after the last dose of study medication Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
- •Male participants should agree to use condoms starting with the first dose of study therapy through 7 month after the last dose of study therapy.
- •Willing to consent to the use of their collected tumor specimen, blood and urine as detailed in the protocol for future scientific research including but not limited to DNA, RNA and protein based biomarker detection.
- •Be ≥ 18 years of age on day of signing informed consent.
- •Wish to preserve their bladder function or be ineligible for cystectomy.
- •Must have undergone transurethral biopsy of the bladder tumor, within 35 days of planned treatment commencement. The patient should have a histologically-confirmed diagnosis of muscle-invasive T2-T4a, N0-1M0 urothelial cell carcinoma of the bladder.
- •Must have undergone maximal transurethral resection of the bladder tumour, to an extent that is judged as safe by the urologist performing the resection, within 35 days of planned treatment commencement.
- •Subjects with tumors of mixed urothelial/non-urothelial cell histology are allowed, but urothelial cell carcinoma must be the predominant histology (>50%). Subjects with predominant or exclusively non-urothelial cell histology are not allowed.
- •Have planned for chemoradiotherapy as definitive treatment.
- •Have a performance status of 0 or 1 on the ECOG Performance Scale
- •Have a bladder function that is accessible for cystoscopic follow up.
排除标准
- •Has DPD deficiency
- •Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy over 10mg daily prednisone (or equivalent) or any other form of immunosuppressive therapy within 14 days prior to registering the patient. Patients with adrenal insufficiency receiving replacement dose steroids are allowed on the trial.
- •Has a known history of active TB (Bacillus Tuberculosis)
- •Hypersensitivity to nivolumab and/or ipilimumab or any of its excipients.
- •Prior or concurrent known additional malignancy of any site unless disease free for 5 years. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer, Stage T1a well differentiated prostatic carcinoma in men (Gleason = 3+3, PSA <5)
- •Has any history of active autoimmune disease, Stevens-Johnson syndrome or Guillain-Barre. Exceptions to this are: a. Patients with autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone b. Patients with controlled Type I diabetes mellitus on a stable dose of insulin regimen
- •Has known history of, or any evidence of active, non-infectious pneumonitis.
- •Has an active infection requiring systemic therapy.
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient’s participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
- •Has concurrent extra-vesical (i.e. urethra, ureter or renal pelvis) urothelial cell carcinoma of the urothelium. Patients who have involvement of the prostatic urethra with urothelial cell cancer may be included if the location can be safely incorporated in the radiation field.
- •Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
- •Has an Human Immunodeficiency Virus (HIV) infection with a PCR detectable viral load.
- •Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
- •Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
- •Extensive or multifocal bladder carcinoma in situ (CIS) precluding curative chemoradiotherapy.
- •Evidence of distant metastatic disease on a CT or FDG PET/CT chest/abdomen/pelvis performed within 28 days prior to study entry. Up to 3 metastatic lymph nodes in the pelvis (below the common iliac arteries) are allowed, if these can be incorporated in the radiotherapy field.
- •Prior pelvic lymphadenectomy
- •Prior pelvic radiotherapy
- •Has had prior intravenous chemotherapy, targeted small molecule therapy, or radiation therapy for treatment of bladder cancer. Prior intravesical BCG and MMC is permitted.
- •Unsuitable for concurrent MMC / capecitabine based ChRT based on pre-existing medical conditions.
- •Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of treatment. An exception is fiducials that are aimed at improving positional stability during the radiotherapy treatment course. These are allowed.
结局指标
主要结局
In the phase Ib study: toxicity scored with CTCAE v 4.03; incidence of dose limiting toxicity (DLT) during the first 6 weeks after start of the combination
In the phase Ib study: toxicity scored with CTCAE v 4.03; incidence of dose limiting toxicity (DLT) during the first 6 weeks after start of the combination
In the phase II study: disease free survival (DFS) and disease free survival-rate (DFS-rate)
In the phase II study: disease free survival (DFS) and disease free survival-rate (DFS-rate)
次要结局
- Overall Survival
- Overall survival-rate
- Response rate according to RECIST 1.1
- Toxicity according to CTCAE v4.03
研究者
Marc Zuurbier
Scientific
Amsterdam UMC
研究点 (2)
Loading locations...
相似试验
招募中
2 期
A Phase 1b-2 study of Mitomycin-C / Capecitabine chemoradiotherapy combined with Ipilumimab and Nivolumab or Nivolumab monotherapy as bladder sparing curative treatment for muscle Invasive bladder Cancer: the CRIMI study.NL-OMON55840Academisch Medisch Centrum50
招募中
不适用
A Phase 1b-2 study of Mitomycin-C / Capecitabine chemoradiotherapy combined with Ipilumimab andNivolumab or Nivolumab monotherapy as bladder sparing curative treatment for muscle Invasivebladder Cancer: the CRIMI studyMuscle invasive bladder cancerMIBCBlaaskanker, spier-invasief blaascarcinoomNL-OMON28813Amsterdam UMC, AMC50
招募中
1 期
A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI StudyUrinary Bladder CancerInvasive Bladder CancerNCT03844256Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)50
Unknown
2 期
Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast CancerMetastasisBreast CancerNCT01196455Croatian Cooperative Group for Clinical Research in Oncology39
进行中（未招募）
1 期
A study to elucidate the effect of gemcitabin and capcitabine in patients with colorectal cancer.Chemotherapy Refractory Metastatic Colorectal CancerMedDRA version: 14.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-004182-33-DKVejle Hospital33